Market Overview
The Europe Viscosupplementation Market is expected to reach a value of
USD 5.6 billion by the end of 2024, and it is further anticipated to reach a market value of
USD 13.0 billion by 2033 at a
CAGR of 9.8%. 
Viscosupplementation includes extracting pathological joint fluid & replacing it with a highly concentrated HA solution, typically 16 to 30 times higher than the original fluid. Some formulations have low rheological properties, like arthritic joint fluid, while others use hyaluronan derivatives (hylans) with better elastoviscosity, similar to healthy joint fluid found in young individuals.
As per the BMJ, viscosupplementation for knee osteoarthritis has raised concerns, with data from 15 placebo-controlled trials involving 6,462 participants revealing a 49% higher risk of serious adverse events compared to placebo (relative risk 1.49; 95% CI 1.12–1.98).
Knee osteoarthritis, a chronic degenerative condition, affects over 560 million people globally and is a leading cause of disability, particularly among older populations. Despite its potential therapeutic benefits, the market for viscosupplementation is under scrutiny due to safety concerns, necessitating a balanced approach to adoption and further innovation to address both efficacy and safety challenges in managing this widespread condition.
Viscosupplementation, a minimally invasive treatment for osteoarthritis, is gaining traction due to rising aging populations and increased demand for non-surgical interventions. Recent trends highlight advancements in hyaluronic acid formulations and their combination with regenerative therapies like PRP (platelet-rich plasma).
Key opportunities lie in expanding market penetration in emerging economies and enhancing product efficacy through innovation. Notable deals include mergers and acquisitions by major pharmaceutical players to strengthen their orthopedic portfolios. Conferences like the Orthopedic Summit and AAOS Annual Meeting discuss cutting-edge developments and clinical outcomes. The sector remains dynamic, driven by innovation, partnerships, and growing awareness of osteoarthritis management.
Key Takeaways
- The Europe Viscosupplementation Market is expected to grow by 7.4 billion, at a CAGR of 9.8% during the forecasted period.
- By Product, the Single Injection Cycle is expected to lead in 2024 & is anticipated to dominate throughout the forecasted period.
- By End User, Hospitals are expected to have a lead throughout the forecasted period.
- Some of the use cases of viscosupplementation include knee osteoarthritis, ankle osteoarthritis, and more.
Use Cases
- Knee Osteoarthritis: Injecting hyaluronic acid into the knee joint to reduce pain and stiffness, improving mobility & function in individuals with knee osteoarthritis.
- Hip Osteoarthritis: Using viscosupplementation to reduce pain and improve joint function in patients suffering from hip osteoarthritis, supporting improved movement and comfort.
- Shoulder Osteoarthritis: Injection of hyaluronic acid into the shoulder joint to reduce pain, increase range of motion, and improve joint function, mainly beneficial for individuals with shoulder osteoarthritis.
- Ankle Osteoarthritis: Its application for symptomatic relief, pain reduction, and improved joint function in patients experiencing osteoarthritis of the ankle, allowing better mobility and comfort.
Market Dynamic
As the elderly population increases, hospital admissions due to traumatic injuries rise, along with the demand for knee osteoarthritis diagnosis and treatment, which leads to increased demand for care, services, & technologies for conditions like osteoporosis and osteoarthritis, which affect bone and joint health, mainly among the elderly. It is essential for providing immediate relief to these patients.
However, its uses face challenges due to associated side effects and the requirement for skilled professionals to perform the procedures. Moreover, the shortage of STEM skills in the
medical industry adds to the struggle to find qualified personnel to administer viscosupplementation. Even after the growing demand for these treatments, addressing these challenges is crucial for sustained market growth.
Research Scope and Analysis
By Product
The Single Injection Cycle is anticipated to drive growth in the European viscosupplementation market by providing an easy treatment option for individuals with osteoarthritis, which smoothly approaches the therapy process, reduces the need for multiple injections, and eases the burden on patients &
healthcare systems. With a single injection providing better relief, it appeals to both patients looking for efficient treatment solutions & healthcare providers focusing on optimizing resources and enhancing patient satisfaction.
In addition, the simplicity of the single injection cycle may attract more patients to consider viscosupplementation as a viable option for managing their joint pain and enhancing mobility. As awareness of this approach grows and its efficiency becomes broadly recognized, it is expected to contribute highly to the expansion of the European viscosupplementation Market, meeting the growth demand for effective osteoarthritis treatments across the region.
By End User
Hospitals are expected to dominate and drive the growth in the European viscosupplementation Market by acting as key points of access for patients looking for treatment in osteoarthritis. As hubs of medical expertise & resources, hospitals provide complete diagnostic services, specialized clinics, & trained healthcare professionals capable of controlling viscosupplementation procedures.
Their role in patient education & awareness-building further supports the adoption of viscosupplementation as a viable treatment option for joint pain & mobility issues. In addition, hospitals provide a centralized location for R&D efforts, supporting collaboration between clinicians, researchers, and
pharmaceutical companies to improve existing therapies and develop innovative solutions. By using it as part of their orthopedic treatment offerings.
The Europe Viscosupplementation Market Report is segmented on the basis of the following
By Product
- Single Injection
- Three Injection
- Five Injection
By End User
- Hospitals
- Ambulatory Surgical Centers
- Orthopedic Clinics
European Country Analysis
Several European countries, like Germany, France, and the UK, play important roles in driving the Europe Viscosupplementation Market's growth. Germany comes out for its strong healthcare infrastructure & large research capabilities, contributing majorly to innovation in viscosupplementation therapies. In addition, France, known for its advanced regulatory framework & clinical expertise, ensures adherence to quality standards & patient safety.
Further, the UK's strategic geographical location & advanced distribution networks support efficient market access for its products throughout Europe. These countries highly contribute to collaboration among industry stakeholders, academia, and healthcare providers, driving development in treatment approaches & enhancing patient outcomes.
With their combined efforts, they address the rising need for effective osteoarthritis treatments, ultimately improving the quality of life for individuals facing joint-related ailments across the continent.
By European Countries
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Competitive Landscape
The competitive landscape of the European viscosupplementation Market consists of a variety of players, like pharmaceutical companies, medical device manufacturers, & healthcare service providers.
These players compete for market share through product innovation, pricing strategies, and distribution networks. In addition, strategic partnerships, mergers, and acquisitions contribute to the dynamic nature of the market, as companies look to expand their reach and strengthen their competitive position in the industry.
Some of the prominent players in the Europe Viscosupplementation Market are:
- Meda AB
- Ferring B.V.
- Sanofi S.A.
- Anika Therapeutics Inc
- Bioventus LLC
- Lifecore Biomedical
- Fidia Pharmaceutici
- Johnson & Johnson Services
- Zimmer Biomet
- Aptissen
- Other Key Players
Recent Developments
- In February 2024, IBSA UK launched a variety of products, notably SINOVIAL, to target musculoskeletal conditions, mainly in Osteoarthritis, as it bridges the gap in osteoarthritis care, providing advanced formulations based on proprietary technology & recent scientific discoveries in viscosupplementation, helping around 10 million arthritis patients in the UK.
- In May 2023, Abiogen Pharma acquired more than ninety-seven percent stake in EffRx Pharmaceuticals SA, a company that develops and markets prescription drugs targeted mainly to musculoskeletal & rare pathologies on European & international markets. Further, the key active agent developed by EffRx absorbs soluble alendronate which belongs to a class of non-hormonal pharmaceuticals known as bisphosphonates, which has been distributed in Italy by Abiogen Pharma.
- In November 2022, Anika Therapeutics, Inc. announced positive results from Phase III Study Cingal showing its superiority over triamcinolone hexacetonide (TH) steroid alone at 26 weeks post-treatment, which also marks the third completed Phase III study of Cingal, all of which have demonstrated its superiority over active ingredients and placebo.
- In April 2022, CarthroniX, Inc. announced the closure of a USD 2.25 million convertible note, led by Pacira BioSciences, Inc., with participation from current investors. The funds would assist the final phases of pre-clinical development for CX-011, an innovative injectable therapeutic targeting mild-to-moderate knee osteoarthritis progression reversal.
Report Details
| Report Characteristics |
| Market Size (2024) |
USD 5.6 Bn |
| Forecast Value (2033) |
USD 13.0 Bn |
| CAGR (2023-2032) |
9.8% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Product (Single Injection, Three Injection, and Five Injection), By End User (Hospitals, Ambulatory Surgical Centers, and Orthopedic Clinics) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Meda AB, Ferring B.V., Sanofi S.A., Anika Therapeutics Inc, Bioventus LLC, Lifecore Biomedical, Fidia Pharmaceutici, Johnson & Johnson Services, Zimmer Biomet, Aptissen, and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Europe Viscosupplementation Market size is estimated to have a value of USD 13.0 billion in 2024
and is expected to reach USD 5.6 billion by the end of 2033.
Some of the major key players in the Europe Viscosupplementation Market are Meda AB, Ferring B.V.,
Sanofi S.A, and many others.
The market is growing at a CAGR of 9.8 percent over the forecasted period.